Calcium-channel modulators for cardiovascular disease (Q36407405)

14 August 2017

1 reference

title

Calcium-channel modulators for cardiovascular disease (English)

1 reference

14 August 2017

Théophile Godfraind

1

1 reference

PubMed ID

16503826

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Emerging Drugs

14 August 2017

1 reference

14 August 2017

11

1 reference

14 August 2017

1

1 reference

14 August 2017

49-73

1 reference

Molecular diversity of voltage-dependent Ca2+ channels

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Nomenclature of voltage-gated calcium channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Receptor sites for Ca2+ channel antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Construction of a high-affinity receptor site for dihydropyridine agonists and antagonists by single amino acid substitutions in a non-L-type Ca2+ channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Structure and regulation of voltage-gated Ca2+ channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Mouse models to study L-type calcium channel function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Functional role of L-type Cav1.3 Ca2+ channels in cardiac pacemaker activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Pharmacology, structure and function of cardiac L-type Ca(2+) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Blood pressure response to angiotensin II, low-density lipoprotein cholesterol and polymorphisms of the angiotensin II type 1 receptor gene in hypertensive sibling pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Genetics of human hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Genetic factors associated with volume-sensitive hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Adducin polymorphism: detection and impact on hypertension and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Global burden of hypertension: analysis of worldwide data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

A new era in hypertension research: discussing the findings of ALLHAT

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Cardiovascular protection and blood pressure reduction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium channel blockers in hypertension: reappraisal after new trials and major meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study e

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Reversibility of left ventricular hypertrophy by antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Pacemaker channels and sinus node arrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium antagonists: effects on cardio-renal risk in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium pumps: structural basis for and mechanism of calcium transmembrane transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium signalling: a historical account, recent developments and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

A comparative functional analysis of plasma membrane Ca2+ pump isoforms in intact cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

The versatility and universality of calcium signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Signal transduction. The calcium entry pas de deux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

The endoplasmic reticulum: one continuous or several separate Ca(2+) stores?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Cytoplasmic signaling pathways that regulate cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Decoding calcium signals involved in cardiac growth and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Ca2+ control of transcription: can we extrapolate signaling cascades from neurons to vascular smooth muscle cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium-calcineurin signaling in the regulation of cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium antagonists and vasodilatation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Selectivity of different calcium antagonists on T- and L-type calcium currents in guinea-pig ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium antagonists and endothelial function: focus on nitric oxide and endothelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2+ channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Alternatively spliced IS6 segments of the alpha 1C gene determine the tissue-specific dihydropyridine sensitivity of cardiac and vascular smooth muscle L-type Ca2+ channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Voltage-gated calcium-channels and antiarrhythmic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Dihydropyridine Ca2+ channel antagonists and agonists block Kv4.2, Kv4.3 and Kv1.4 K+ channels expressed in HEK293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Symposium on regression of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

The L-arginine-nitric oxide pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Erythropoietin depresses nitric oxide synthase expression by human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Lacidipine prevents endothelial dysfunction in salt-loaded stroke-prone hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Structure-function relationships of calcium antagonists. Effect on oxidative modification of low density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Oxidative stress in arterial hypertension: role of NAD(P)H oxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Does superoxide underlie the pathogenesis of hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

NAD(P)H oxidase: role in cardiovascular biology and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Oxidant signaling in vascular cell growth, death, and survival : a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Mechanisms for inducible control of angiotensinogen gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Angiotensin, inflammation, hypertension, and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Workshop: mechanisms and cardiovascular damage in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

New expression profiles of voltage-gated ion channels in arteries exposed to high blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Ion channels and vascular tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Upregulation of L-type Ca2+ channels in mesenteric and skeletal arteries of SHR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Atherogenesis, calcium and calcium antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Toll to be paid at the gateway to the vessel wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Molecular bases of the acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Atherosclerosis, calcium, and calcium antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: a comparison with apolipoprotein-E deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium channel blocker inhibits Western-type diet-evoked atherosclerosis development in ApoE-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display alpha-/beta-adrenoceptor antagonist and long-acting antihypertensive activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Inhibition of mitogen-mediated proliferation of rat vascular smooth muscle cells by labedipinedilol-A through PKC and ERK 1/2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Combinatorial synthesis and screening of a chemical library of 1,4-dihydropyridine calcium channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Selective phenylalkylamine block of I(Kr) over other K(+) currents in guinea-pig ventricular myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Particular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastastic breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Treatment of isolated systolic hypertension: the SHELL study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Semi-preparative chromatographic purification of the enantiomers S-(-)-amlodipine and R-(+)-amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.1.49

21 January 2018

Identifiers

DOI

10.1517/14728214.11.1.49

1 reference

14 August 2017

1 reference

PubMed ID

16503826